According to a randomized, placebo-controlled study, “chronic administration of CBD reduces ambulatory blood pressure in those with untreated and treated hypertension.” In addition, a “lack of serious AEs (adverse effects) implies safety and tolerability”.
The study was conducted by researchers at the University Hospital of Split and the University of Split School of Medicine, both in Croatia. It’s being published in the upcoming issue of the peer-reviewed journal Cannabis and Cannabinoid Research, with the abstract published ahead of print by the US National Library of Medicine.
The primary aim of this randomized, triple-blind, placebo-controlled, and crossover study “was to examine the influence of chronic CBD on 24-h ambulatory BP [blood pressure] and arterial stiffness in hypertensive patients.”
For the study seventy patients with mild or moderate primary hypertension, who were untreated or receiving standard of care therapy, were randomly assigned to receive either 5 weeks of oral CBD or placebo-matched controls.
Following a >2-week washout period, patients were crossed over to alternate therapy. The primary outcome of the study was dynamic in 24-h ambulatory BP and was assessed using two-way repeated measure analysis of variance.
“Administration of CBD reduced average 24 h mean, systolic, and diastolic BP after 2.5 weeks (-3.22±0.90 mmHg [95% confidence interval -1.01 to -5.44 mmHg], -4.76±1.24 mmHg [-1.72 to -7.80 mmHg], and -2.25±0.80 mmHg [-0.30 to -6.01 mmHg], respectively (all p<0.05)”, states the study. However, “these values largely remained stable following the uptitration of CBD dosing. There were no changes in liver enzymes or serious adverse events (AEs).”
Researchers found that “There was no significant difference in pulse wave velocity (group×factor interaction: F=1.50, p=0.226) at different time points, regardless of the intervention arm.
The study concludes:
In conclusion, chronic administration of CBD reduces ambulatory BP in those with untreated and treated hypertension. In addition, lack of serious AEs implies safety and tolerability of the above-noted CBD formulation.
